Literature DB >> 2207767

Aggressive phase multiple myeloma: a terminal anaplastic transformation resembling high-grade lymphoma.

S L Allen1, M Coleman.   

Abstract

The term "aggressive phase" has been applied in multiple myeloma to the development of rapidly enlarging extramedullary soft tissue masses or of bone marrow transformation with histologic features resembling high-grade or anaplastic lymphomas. One hundred and one patients who fulfilled this definition were identified in a review of the literature. Eighty-six patients had soft tissue or visceral involvement and 15 bone marrow involvement. The mean age at initial diagnosis of myeloma was 53 years, suggesting that the aggressive phase may be more likely to develop in younger patients. A disproportionate percentage of these patients have an IgA gammopathy. Following the onset of the aggressive phase, these patients have a rapidly fatal course, refractory to therapy, with a mean survival of less than 3.5 months. It is hypothesized that this aggressive phase represents part of the natural history of multiple myeloma, analogous to the terminal transformations associated with other relatively indolent myeloproliferative and lymphoproliferative disorders. Studies are reviewed supporting the proposition that the clinical and morphological changes associated with the aggressive phase result from a clonal evolution of the original malignant cell line and do not represent the development of an independent new neoplasm.

Entities:  

Mesh:

Year:  1990        PMID: 2207767     DOI: 10.3109/07357909009012059

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  7 in total

1.  A case of aggressive myeloma recognized shortly after the remission following high-dose chemotherapy with autologous peripheral blood stem cell transplantation.

Authors:  Kaname Ueda; Katsuhiro Miura; Yoshihiro Hatta; Sumiko Kobayashi; Toshitake Tanaka; Atsuko Hojo; Hikaru Ishizuka; Umihiko Sawada; Yoshimasa Kura; Jin Takeuchi
Journal:  Int J Hematol       Date:  2010-08-20       Impact factor: 2.490

2.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

Authors:  Marta Chesi; Davide F Robbiani; Michael Sebag; Wee Joo Chng; Maurizio Affer; Rodger Tiedemann; Riccardo Valdez; Stephen E Palmer; Stephanie S Haas; A Keith Stewart; Rafael Fonseca; Richard Kremer; Giorgio Cattoretti; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

3.  Relapsing Extramedullary Multiple Myeloma Presenting As Acute Liver Failure.

Authors:  Hafiza Wajeeha Javaid; Farrukh Munir; Saman Bahram
Journal:  Cureus       Date:  2021-12-28

4.  Morphological Transformation of Myeloma Cells into Multilobated Plasma Cell Nuclei within 7 Days in a Case of Secondary Plasma Cell Leukemia That Finally Transformed as Anaplastic Myeloma.

Authors:  Akihito Fujimi; Yasuhiro Nagamachi; Naofumi Yamauchi; Yuji Kanisawa
Journal:  Case Rep Hematol       Date:  2017-12-21

5.  Pleomorphic Multinucleated Plasma Cells Simulating Megakaryocytes in an Anaplastic Variant of Myeloma.

Authors:  Shivangi Harankhedkar; Ruchi Gupta; Khaliqur Rahman
Journal:  Turk J Haematol       Date:  2018-02-06       Impact factor: 1.831

Review 6.  A case of coincident multiple myeloma and non-Hodgkin's lymphoma.

Authors:  G C Lee; J S Hong; K H Lee; S B Kim; S W Kim; C W Suh; J S Lee; H S Chi; S H Kim
Journal:  Korean J Intern Med       Date:  1994-07       Impact factor: 2.884

7.  Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.

Authors:  Masuho Saburi; Masao Ogata; Yasuhiro Soga; Yoshiyuki Kondo; Ryo Kurimoto; Kazuhito Itani; Kazuhiro Kohno; Hiroki Uchida; Toshiyuki Nakayama
Journal:  J Clin Exp Hematop       Date:  2020
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.